Are RDY insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RDY leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Stock Ratings / Health Care / RDY / insiders

ELAN (45) BMRN (74) SMMT (40) SYRE (55) ⌘ Pro Terminal →

Dr. Reddy's Laboratories Ltd (RDY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$14.13 -0.28% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.10

Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $11.83B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RDY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.13 (-0.28% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, RDY ranks #127 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RDY compare to ELAN and BMRN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RDY?

▼

For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #127 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.10 (-0.24%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 6.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDY)Realized 20D OHLCV Swing Band: ±3.6%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY RDY SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (20% of score)

20D Institutional Volume Accumulation (±3.6% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)

Capital intensity & 13.9% operating margin leave 9 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$12.75+3.5% Next Q

Q2 (-2Q)

Grade C$13.19+7.3% Next Q

Q3 (-1Q)

Grade C$14.15-0.1% Next Q

Current

Grade C$14.13+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RDY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, RDY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.65) or 200D SMA ($13.23) invalidates the momentum regime and cuts Target Base ($14.51) toward Bear Floor ($11.32).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RDY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RDY Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RDY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RDY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RDY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RDY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.84%⚡ TESTING RESISTANCE

2026-11-03O $14.11H $14.17L $14.11C $14.13VOL 1.83M

RES: $14.27SUP: $11.65SMA50: $12.65SMA200: $13.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RDY Butterfly Map → + Track RDY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RDY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDY)

Health Care Rank #127 of 1016 ⚔️ ELAN vs RDY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RDY vs. ELAN, BMRN, SMMT, SYRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dr. Reddy's Laboratories Ltd (RDY) ranks #127 by composite RQD confidence (64/100, grade C) and #93 by equity capitalization ($11.83B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RDY at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RDY ACTIVE Dr. Reddy's Laboratories Ltd	C	64/100	32.8x	—	9.9%	-0.28%	$11.83B	Benchmark Subject
ELAN Elanco Animal Health Incorporated	D	45/100	—	55.0%	-2.5%	+4.51%	$11.52B	/elan-vs-rdy →
BMRN BioMarin Pharmaceutical Inc.	B	74/100	31.9x	77.7%	6.0%	-1.83%	$11.33B	/bmrn-vs-rdy →
SMMT Summit Therapeutics Inc.	D-	40/100	—	—	-35.0%	-7.67%	$12.82B	/smmt-vs-rdy →
SYRE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-1.09%	$10.08B	/syre-vs-rdy →

2. RDY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Dr. Reddy's Laboratories Ltd (RDY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $11.83B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. RDY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RDY compare to ELAN and BMRN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RDY?

Where is RDY trading relative to its 50-day, 200-day, and 52-week technical levels?

RDY last traded at $14.13 (-0.28% on volume of 1,932,026 shares), positioning the stock +11.70% above its 50-day simple moving average ($12.65) and +6.80% above its 200-day simple moving average ($13.23). Across its 52-week range of $11.36 to $15.67, RDY sits at the 64.3% percentile with a 14-day RSI of 76.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±3.6% ($13.62 to $14.64).

Direct Sub-Reports: RDY RQD Cockpit RDY 12M Forecast RDY Earnings & Move RDY Dividends & DRIP RDY Insiders & 13F RDY Whale Options RDY Profit Sankey RDY News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RDY — Dr. Reddy's Laboratories Ltd: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:10:15Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

RDY scores 64 out of 100, grade C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine: 11 / 20. this pillar reflects ROIC of 9.9% and FCF yield of 2.21%. The FCF yield is modest relative to a 30.5x forward P/E, which implies the market is pricing in growth that the current cash generation does not yet support.
Whale 13F Flow: 13 / 20. this reflects institutional accumulation and options positioning. The score is moderate, indicating neither strong conviction nor clear distribution in the source data.
Insider Conviction: 12 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow. The moderate score suggests insider activity is neither a strong tailwind nor a warning sign.
Macro Regime Fit: 12 / 20. beta is 1.05 with sector sensitivity noted. RDY roughly tracks broad market volatility, so it is unlikely to cushion a risk-off move nor to dramatically outperform in a rally.
Forensic Balance Sheet: 16 / 20. the Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. This is the strongest pillar and points to a financially sound balance sheet.

For a prospective investor, the upside case rests on balance sheet quality and the market's tolerance for a premium multiple. The valuation tradeoff is that a trailing P/E of 32.8 and EV/EBITDA of 21 leave limited margin for error if growth or margins disappoint. The rating's "Hold" label reflects that balance-sheet strength is offset by weak cash-return metrics and a demanding valuation.

2. Business Model, Unit Margins & SEC Financial Trajectory

Dr. Reddy's Laboratories Ltd is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, the company reports an operating margin of 13.9% and a net margin of 10.9%. Specific product lines, customer segments, and revenue mix are —

Per the market data, operating margin is 13.9%, net margin is 10.9%, and ROIC is 9.9%. Gross margin is reported as 0%, which should be read as a data limitation rather than a verified economic fact. The Altman Z-Score is 3.74 and the Piotroski F-Score is 8/9, both pointing to financial strength. Debt/Equity is 0.39. Multi-period financial statements are not provided, so trend direction cannot be assessed.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, indicating financial strength. With Fundamental Cash Engine at 11/20 (ROIC 9.9%, FCF yield 2.21%) and Institutional Whale Flow at 13/20, sustained execution supports upside toward the top of the $11.36 – $15.67 52-week range.
🐻 Primary Bear Case: Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.05 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signals are recorded. —

From a sector-analysis standpoint only: pharmaceutical preparation companies are commonly exposed to regulatory decisions, drug pricing, and generic competition, but none of these exposures are documented for RDY in the source data. Investors should treat these as open questions rather than established risks for this issuer.

Key Question #1: What do the recent earnings results (the 2026-10-23 Q2 release) show for growth and margin trends?
Key Question #2: What is the analyst consensus rating and price target, and how do they compare with the current $14.11 price?
Key Question #3: What is the institutional (13F) and insider (Form 4) ownership and activity pattern over recent quarters?

RDY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dr. Reddy's Laboratories Ltd (RDY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RDY Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Yahoo Finance report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Dr. Reddy's Laboratories(RDY) Stock Options Chain | Quotes & News

Moomoo report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call Presentation (NYSE:RDY) 2026-10-23

Seeking Alpha report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Dr Reddy's Laboratories Ltd (RDY) Shares Surge 4.1% -- What GF S

GuruFocus report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

TradingView report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Dr. Reddy's Laboratories (NYSE:RDY) Stock Jumps 4.8% After Strong Earnings

MarketBeat report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Quiver Quantitative • 1d ago

Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings

Quiver Quantitative report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Fintel • 5d ago

Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action Indicated

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RDY Bull vs. Bear Conversation Board — What's Your Call at $14.13?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDY 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $18.56 (+31.0%)

📌 Pinned Debate

Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39,

Don't sleep on RDY's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, indicating financial strength.. Beta of 1.05 means it moves fast when momentum turns, and the 5-pillar RQD gauge (64/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 64/100 quality, though with 1.05 beta I'm scaling in with half-size at $14.17 and keeping dry powder in case we test $13.18.

FA FadeTheHype Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $11.90 (-16.0%)

Spot @ $14.17

Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.

Sitting on the sidelines or leaning short RDY above $14.17. Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.. Until Fundamental Cash Engine (11/20) and FCF yield (2.21%) inflect higher, upside is capped near $15.67.